Committee for Advanced Therapies (CAT): 14-16 February 2024, European Medicines Agency, Amsterdam, the Netherlands, from 14 February 2024 to 16 February 2024

Submitted by Anonymous (not verified) on 30 April 2024 - 16:20

Committee for Advanced Therapies (CAT): 14-16 February 2024, European Medicines Agency, Amsterdam, the Netherlands, from 14 February 2024 to 16 February 2024

Ketoprofen : call for scientific data for use in CVMP assessment work of ketoprofen: review of the CVMP opinion for the establishment of maximum residue limits

Submitted by Anonymous (not verified) on 30 April 2024 - 15:24

Ketoprofen : call for scientific data for use in CVMP assessment work of ketoprofen: review of the CVMP opinion for the establishment of maximum residue limits

Human medicines European public assessment report (EPAR): Hexacima, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed), Date of authorisatio

Submitted by Anonymous (not verified) on 30 April 2024 - 14:14

Human medicines European public assessment report (EPAR): Hexacima, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed), Date of authorisation: 17/04/2013, Date of refusal: 22/02/2013, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Bimzelx, bimekizumab, Date of authorisation: 20/08/2021, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 30 April 2024 - 13:57

Human medicines European public assessment report (EPAR): Bimzelx, bimekizumab, Date of authorisation: 20/08/2021, Revision: 6, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness